Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
A PHASE1/PHASE2 clinical study on Hereditary Hemorrhagic Telangiectasia, this trial is completed. The trial is conducted by National Institute of Neurological Disorders and Stroke (NINDS) and has accumulated 12 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Phase: NA → PHASE1_PHASE2
-
Aug 2023 — Oct 2023 [monthly]
Completed NA
-
Dec 2021 — Aug 2023 [monthly]
Completed NA
▶ Show 7 earlier versions
-
Oct 2021 — Dec 2021 [monthly]
Completed NA
-
Jan 2021 — Oct 2021 [monthly]
Completed NA
-
Oct 2019 — Jan 2021 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Feb 2019 — Oct 2019 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Feb 2019 [monthly]
Recruiting NA
-
Jun 2018 — Aug 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Neurological Disorders and Stroke (NINDS)
- Sunnybrook Health Sciences Centre
- The Hospital for Sick Children
- Toronto Metropolitan University
- Unity Health Toronto
- University of California, San Francisco
- University of Toronto
For direct contact, visit the study record on ClinicalTrials.gov .